Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 17, Issue 10, Pages 2890-2893Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2007.02.065
Keywords
makaluvamine; analog; HCT-116; MCF-7; MDA-MB-468; topoisomerase II
Categories
Funding
- NCI NIH HHS [P50 CA089019-01, P50 CA089019] Funding Source: Medline
Ask authors/readers for more resources
Twelve analogs of makaluvamines have been synthesized. These compounds were evaluated for their ability to inhibit the enzyme topoisomerase II. Five compounds were shown to inhibit topoisomerase catalytic activity comparable to two known topoisomerase II targeting control drugs, etoposide and m-AMSA. Their cytotoxicity against human colon cancer cell line HCT-116 and human breast cancer cell lines MCF-7 and MDA-MB-468 has been evaluated. Four makaluvamine analogs exhibited better IC50 values against HCT-116 as compared to control drug etoposide. One analog exhibited better IC50 value against HCT-116 as compared to m-AMSA. All 12 of the makaluvamine analogs exhibited better IC50 values against MCF-7 and MDA-MB-468 as compared to etoposide as well as m-AMSA. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available